Nevro (NVRO) might move higher on growing optimism about its earnings prospects, which is reflected by its upgrade to a Zacks Rank #2 (Buy).

Fintel reports that on February 7, 2025, Piper Sandler upgraded their outlook for Nevro (NYSE:NVRO) from Underweight to ...

Q4 2024 Management View CEO Daniel Scavilla highlighted record revenue of $2.519 billion for 2024, driven by $951 million in growth and a 61% increase versus the prior year. Non-GAAP EPS for the year ...

Nevro (NVRO) could be a solid choice for investors ... the stock -- for the current and following years is tracked by the system. The power of a changing earnings picture in determining near ...

Nevro has developed and commercialized the Senza spinal cord stimulation (SCS) system, an evidence-based, non-pharmacologic neuromodulation platform for the treatment of chronic pain. HF10 therapy ...

The CEO of Globus Medical said the deal will enable the Audubon company to expand into new markets for future growth.

Nevro Corp is a medical device company. Its key product is the HFX spinal cord stimulation (SCS) platform, which includes the Senza SCS system, an evidence-based neuromodulation system for the ...

Nevro's comprehensive HFX™ spinal cord stimulation (SCS) platform includes the Senza® SCS system and support services for the treatment of chronic pain of the trunk and limb and painful diabetic ...

Detailed price information for Globus Medical Inc (GMED-N) from The Globe and Mail including charting and trades.